Alyeska Investment Group L.P. Makes New $1.63 Million Investment in Seaport Therapeutics, Inc. $SPTX

Key Points

• Alyeska Investment Group acquired 75,000 Seaport Therapeutics shares worth approximately $1.63 million, while TRV GP VI LLC established a much larger position valued at about $44.8 million.
• Analyst sentiment is mixed: six analysts rate the stock “Buy,” three rate it “Hold,” and two rate it “Sell.” The consensus rating is “Hold,” with an average price target of $37.33.
• Seaport Therapeutics reported quarterly EPS of -$1.78, missing the consensus estimate of -$0.71. Shares opened at $23.61, compared with a 52-week range of $14.85 to $28.38.

Alyeska Investment Group L.P. bought a new stake in shares of Seaport Therapeutics, Inc. (NASDAQ:SPTX - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 75,000 shares of the company's stock, valued at approximately $1,629,000. Alyeska Investment Group L.P. owned approximately 0.14% of Seaport Therapeutics as of its most recent SEC filing.

Separately, TRV GP VI LLC bought a new position in Seaport Therapeutics during the 2nd quarter valued at approximately $44,769,742.

Insider Activity at Seaport Therapeutics

In related news, Director Robert J. Hombach bought 13,000 shares of the business's stock in a transaction dated Monday, June 22nd. The shares were purchased at an average price of $18.14 per share, with a total value of $235,820.00. Following the transaction, the director owned 13,000 shares in the company, valued at $235,820. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Analysts Set New Price Targets

SPTX has been the topic of several recent analyst reports. Weiss Ratings began coverage on shares of Seaport Therapeutics in a research report on Tuesday, August 11th. They set a "sell (d+)" rating on the stock. HC Wainwright reissued a "buy" rating and issued a $50.00 target price on shares of Seaport Therapeutics in a report on Thursday, August 20th. BNP Paribas Exane cut Seaport Therapeutics to a "market perform" rating in a research note on Tuesday, May 26th. Seaport Research Partners set a $32.00 price objective on Seaport Therapeutics in a research report on Tuesday, August 25th. Finally, JonesTrading assumed coverage on shares of Seaport Therapeutics in a research note on Wednesday, August 26th. They set a "buy" rating and a $32.00 target price on the stock. Six research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $37.33.

Seaport Therapeutics Trading Down 0.3%

NASDAQ:SPTX opened at $23.61 on Wednesday. The company has a market cap of $1.26 billion and a P/E ratio of -1.95. The business has a 50 day moving average price of $22.02. Seaport Therapeutics, Inc. has a 1 year low of $14.85 and a 1 year high of $28.38.

Seaport Therapeutics (NASDAQ:SPTX - Get Free Report) last issued its quarterly earnings data on Monday, August 3rd. The company reported ($1.78) EPS for the quarter, missing analysts' consensus estimates of ($0.71) by ($1.07). On average, equities research analysts expect that Seaport Therapeutics, Inc. will post -4.6 EPS for the current fiscal year.

Seaport Therapeutics Profile

Seaport Therapeutics Inc is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety and other debilitating neuropsychiatric disorders. Seaport Therapeutics Inc is based in BOSTON.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source